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Background: Recent studies have shown Growth differentiation factor–15 (GDF-15) that is a member of the
transforming growth factor β (TGF-β) superfamily might be a potential predictive cytokine for the prognosis of
Acute coronary syndrome (ACS). However, there are discrepancies in these studies.
Methods: Publication searches of the PubMed/Medline and EMBASE databases were performed without any time
or ethnicity restrictions. The inclusion and exclusion criteria, when clear, were addressed. Random effects models
were used for all analyses. Publication bias was tested using funnel plots and the Egger test.
Results: We identified eight eligible studies that provided mortality data. Five of these studies provided recurrent
myocardial infarction (MI) data. The maximal duration of follow-up ranged from 6 months to 6 years. A significant
association was found between the patients with the highest and lowest GDF-15 levels (overall analyses) in terms of
mortality (p < 0.00001; RR = 6.08; 95 % CI = 4.79–7.71) and recurrent MI (p < 0.00001; RR = 1.76; 95 % CI = 1.49–2.07). We
also found significant associations between the subgroup analyses stratified by ACS types, cutoff points and follow-up
durations (p < 0.001). The combined hazard ratio was high for GDF-15 to ACS (HR = 1.656, 95 % CI = 1.467–1.871).
Conclusion: High plasma GDF-15 levels are associated with an increased risk of mortality and recurrent MI in patients
with ACS.Background
Acute coronary syndrome (ACS), including ST-segment
elevation myocardial infarction (STEMI), non-ST-segment
elevation myocardial infarction (NSTEMI) and unstable an-
gina pectoris (UAP), result from the rupture or erosion of
vulnerable atherosclerotic plaque [1], and death and recur-
rent myocardial infarction (MI) can occur at any time after
the first attack episode. Currently, even with medication
and coronary intervention, the prognosis for ACS patients
is still not good [2]. Therefore, the early evaluation of ACS
and its timely treatment are particularly important.
Growth differentiation factor–15 (GDF-15) is a member
of the transforming growth factor β (TGF-β) superfamily.
GDF-15 primarily regulates multiple cellular functions, as
well as the biological processes underlying the growth of* Correspondence: hanbincui@hotmail.com; zhuhongyan845@163.com
†Equal contributors
1Department of Cardiovascular, Ningbo First Hospital, Ningbo 315010, China
Full list of author information is available at the end of the article
© 2016 Zhang et al. Open Access This article
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zemultiple organs and the differentiation and renovation of
tissues [3]. Researchers have verified that GDF-15 exerts a
suppressive function in the progress, invasiveness, and
metastasis of tumors by facilitating the apoptosis of tumor
cells [4]. In addition, GDF-15 is also related to cardiovas-
cular diseases, such as heart failure [5], cardiac hyper-
trophy [6], and coronary heart disease (CHD) [7]. Recent
studies have shown that GDF-15 might be a potential pre-
dictive cytokine for the prognosis of ACS and, therefore,
might assist physicians in evaluating the prognoses of
ACS patients [8]. Studies examining the association be-
tween GDF-15 and ACS prognosis have included research
on patient mortality [7, 9–15] and recurrent MI [9–12,
15]. However, there have been discrepancies in these
studies, including the target participants, follow-up period,
and patient ethnicity. Hence, this meta-analysis was per-
formed to investigate the role of GDF-15 in predicting the
prognosis of ACS patients.is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhang et al. BMC Cardiovascular Disorders  (2016) 16:82 Page 2 of 7Methods
Inclusion criteria
We performed a meta-analysis to determine whether
GDF-15 could predict the prognoses of ACS patients.
Studies that had a follow-up duration of least 6 months
and that examined the correlation between plasma
GDF-15 levels and the prognoses of ACS patients were
collected. The quality of each included study has been
tested under the Meta-analysis of Observational Studies
in Epidemiology (MOOSE) [16]. The MOOSE systemic
assessments included the following criteria: 1) a clear
explanation of the inclusion and exclusion criteria, 2)
the attrition rate of the samples during the follow-up
period, 3) a clear explanation of the outcomes and
outcome assessments, 4) a sufficient follow-up period, 5)
appropriate statistical analyses, and 6) identification of
the important confounding and prognostic factors. All
items had the following answer options: yes/no/unclear
information to answer the question. When a criterion
was fulfilled, a score of 1 was given; a score of 0 was
given if a criterion was unclear, and −1 was given if a
criterion was not achieved. The MOOSE assessment
of each study was discussed and carefully evaluated
by all authors.
Study selection
The study selection was based on an online search of
the PubMed/MEDLINE and EMBASE databases, with-
out any language restrictions; studies published before
November 14, 2014 were included. The following
medical subject headings were used for the publication
search: “ST-segment elevation myocardial infarction,
STEMI, Non-ST-segment elevation myocardial infarc-
tion, NSTEMI, Unstable angina pectoris, UAP, AcuteFig. 1 Flowchart of selection process in the meta-analysiscoronary syndrome, ACS, growth differentiation factor-
15, GDF-15, Placental growth factor, PGF, macrophage
inhibitory cytokine-1, MIC-1”. The terms were then
combined using Boolean the operators “OR, AND”. We
extracted the data from individual studies that included
the first author’s name, year of publication, ethnicity,
participants, outcome data (mortality and recurrent MI),
and maximal follow-up years, as well as methods that
stratified the GDP-15 levels. The extraction was
performed by two independent reviewers (SZ and DD).
Statistical analysis
Review Manager 5.3 and STATA 11.0 statistical soft-
ware were used for the meta-analysis [17]. Statistical
heterogeneity was tested using Cochran’s Q statistic
and I2 tests [18]. The random effects model was
used for all meta-analyses. The calculated GDF-15
concentration data were extracted from the initial




We retrieved 73 studies from PubMed/MEDLINE and
186 studies from EMBASE (Fig. 1). After removing
duplicates, 158 of 194 studies were excluded based on
title and abstract reviews. In the remaining 36 studies,
there were seven reviews, nine studies based on animals,
nine studies with different participants, and three studies
with inadequate data. Finally, eight articles were in-
cluded in our meta-analysis, including 4 NSTEMI
studies, 2 STEMI studies and 2 other studies that did
not clearly provide the types of ACS. No unstable angina
pectoris data were found.
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Table 1. Eight studies, including 8903 participants, inves-
tigated the association between GDF-15 and mortality.
Five of these studies, including 7193 participants, inves-
tigated the association between GDF-15 and recurrent
MI. The maximal follow-up duration ranged from
6 months to 6 years.Association between GDF-15 and the ACS prognosis
In addition to comparing the prognoses of the ACS
patients with the highest and lowest GDF-15 levels
(overall analyses), we also performed subgroup analyses
based on the ACS types and a stratification of the
GDF-15 values: <1200 ng/L, 1200–1800 ng/L, and
>1800 ng/L. Moreover, based on the included studies,
we stratified the follow-up duration into “>1 years”
and “≤1 years”. Patient mortality and recurrent MI
data were analyzed (Table 2, Additional file 1: Figure S1
and Additional file 2: Figure S2).
For the mortality analyses, a significant association
was found in the overall analyses (p < 0.00001, RR = 6.08,
95 % CI = 4.79–7.71) and subgroup analyses of ACS
(p < 0.00001, RR = 6.03, 95 % CI =3.66–9.93), NSTEMI
(P < 0.00001, RR = 5.94, 95 % CI = 4.38–8.05) and
STEMI (p < 0.00001, RR = 8.24, 95 % CI = 3.35–20.25).
Positive results were also revealed in the subgroup analyses
stratified by GDF-15 Cutoff Point (<1200 ng/L vs. 1200–
1800 ng/L:p < 0.00001, RR = 2.23, 95 % CI = 1.66–2.99;
1200–1800 ng/L vs. > 1800 ng/L:p < 0.00001, RR = 2.76,
95 % CI = 2.28–3.34; and >1800 ng/L vs. < 1200 ng/
L:p < 0.00001 ng/L, RR = 6.22, 95 % CI = 4.77–8.10).
As for subgroup analyses stratified by follow-up
duration, positive results were also obtained for the
≤1 year (p < 0.00001, RR =8.83, 95 % CI = 5.32–14.66)
and >1 year subgroups (p < 0.00001, RR = 5.47, 95 %
CI = 4.18–7.16).Table 1 The characteristics of the studies included in the meta-anal
Author/year/ethnicity Participants Outcomes F
Kempf T/2009/Europeans [7] ACS (n = 877) M 6
Bonaca MP/2011/Europeans [9] ACS (n = 3501) M, R 2
Wollert KC/2007(1)/Europeans [10] NSTEMI (n = 2079) M, R 2
Damman P/2014/Europeans [11] NSTEMI (n = 1151) M, R 5
Wollert KC/2007(2)/Europeans [12] NSTEMI (n = 2081) M, R 1
Eggers KM/2010/Europeans [13] NSTEMI (n = 950) M 5
Kempf T/2007/Europeans [14] STEMI (n = 741) M 1
Eitel I/2011/Europeans [15] STEMI (n = 238) M, R 0
SAP stable angina pectoris, ACS acute coronary syndrome, NSTEMI non-ST-elevation
R recurrent MI, athe maximum follow up year, bthe calculated risk radio based on thFor the recurrent MI analyses, a significant association
was observed in the overall analyses (p < 0.00001, RR =
1.76, 95 % CI = 1.49–2.07) and in the subgroup analyses
of NSTEMI (p < 0.00001, RR = 1.66, 95 % CI = 1.35–2.03)
and ACS (p < 0.00001, RR = 2.02, 95 % CI = 1.56–2.61).
A significant association was also found when comparing
the following GDF-15 cutoff points: 1200–1800 ng/L vs.
>1800 ng/L (p < 0.00001, RR = 1.49, 95 % CI = 1.17–1.89)
and >1800 ng/L vs. <1200 ng/L (p < 0.00001, RR = 1.66,
95 % CI = 1.35–2.03). As for the subgroup analyses strati-
fied by the follow-up durations, a positive result was found
only in the >1 year follow-up duration (p < 0.00001,
RR =1.84, 95 % CI =1.54–2.19); we did not find a sig-
nificant result for follow-up periods ≤1 year (P = 0.08,
RR = 1.42, 95 % CI = 0.96–2.08).
Heterogeneity of the current study
High heterogeneity was found in the comparison of
the recurrent MI between the GDF-15 levels of
<1200 ng/L and 1200 to 1800 ng/L (I2 = 65 %).
Heterogeneity was low for all the above mentioned
analyses (I2 <27 %).
The combined prognostic data of hazard ratio
Hazard ratio (HR) was obtained in seven studies [7, 9,
10, 12–15], which was on the association of the GDF-15
and mortality or recurrent of MI. However, after sensi-
tive analysis, we excluded a study [15] that could lead to
high heterogeneity to the overall meta-analysis. Our re-
sults showed a significant high HR (HR = 1.656, 95 % CI =
1.467–1.871, I2 = 0 %) for GDF-15 to the ACS (Fig. 2).
Discussion
Our meta-analysis identified eight studies, including
8903 participants, and attempted to evaluate the predict-
ive value of plasma GDF-15 levels in the prognosis of
ACS patients by calculating the risk of mortality andysis
ollow-upa Comparisons (ng/L) RR [95 %CI]b MOOSE
<1200, 1200–1800, >1800 8.5 [3.81, 18.99] 6
<1362 4.99 [2.82, 8.83] 5
≥1362
<1200, 1200–1800, >1800 6.11 [3.35, 11.16] 6
<1200, 1200–1800, >1800 5.54 [3.18, 9.64] 6
<1200, 1200–1800, >1800 9.12 [4.93, 16.85] 4
<1200, 1200–1800, >1800 4.3 [2.44, 7.58] 6
<1200, 1200–1800, >1800 6.66 [2.43, 18.23] 6
.5 <1319 19 [2.58, 139.66] 4
≥1319
myocardial infarction, STEMI ST-elevation myocardial infarction, M mortality,
e mortality, MOOSE meta-analysis of observational studies in epidemiology
Table 2 The association between GDF-15 concentration and ACS prognosis
Comparison Participants RR [95 %CI] p value I2
Mortality
ACS type Overall 8903 6.08 [4.79, 7.71] <0.00001 0 %
ACS 4123 6.03 [3.66, 9.93] <0.00001 11 %
NSTEMI 4038 5.94 [4.38, 8.05] <0.00001 8 %
STEMI 742 8.24 [3.35, 20.25] <0.00001 0 %
Cutoff Point <1200 VS 1200–1800 5551 2.23 [1.66, 2.99] <0.00001 0 %
1200–1800 VS >1800 4985 2.76 [2.28, 3.34] <0.00001 0 %
<1200 VS >1800 5164 6.22 [4.77, 8.10] <0.00001 0 %
Follow up duration >1 years 6744 5.47 [4.18, 7.16] <0.00001 0 %
≤1 years 2159 8.83 [5.32, 14.66] <0.00001 0 %
Recurrence of MI
ACS type Overall 7193 1.76 [1.49, 2.07] <0.00001 5 %
ACS 3501 2.02 [1.56, 2.61] <0.00001 NA
NSTEMI 3454 1.66 [1.35, 2.03] <0.00001 0 %
STEMI 238 1.00 [0.39, 2.58] 1.00 NA
Cutoff Point <1200 VS 1200–1800 3766 1.10 [0.75, 1.59] 0.64 65 %
1200–1800 VS >1800 3402 1.49 [1.17, 1.89] 0.0010 27 %
<1200 VS >1800 3454 1.66 [1.35, 2.03] <0.00001 0 %
Follow up duration >1 years 5538 1.84 [1.54, 2.19] <0.00001 5 %
≤1 years 1655 1.42 [0.96, 2.08] 0.08 0 %
NA not applicable, the units of GDF-15 concentration is ng/L
Fig. 2 Funnel plots of GDF-15 with mortality and recurrent MI
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higher GDF-15 levels indicated a higher risk for ACS
mortality and recurrent MI. This association also
remained when the GDF-15 levels were stratified by the
cutoff point, which might be valuable in terms of the risk
stratification of ACS prognoses because it has been previ-
ously reported that 1800 ng/L GDF-15 levels may be an
ideal cutoff value for several disease states [19]. Moreover,
we also found significant associations between GDF-15
levels and subsequent ACS events. Furthermore, we found
high HR for GDF-15 to ACS. These findings might assist
with monitoring the prognoses of ACS patients.
GDF-15 has been described as a promising cardio-
protective agent [20]. Previous studies have reported that
higher expression levels of GDF-15 could predict deterior-
ating conditions for heart disease patients, particularly ACS
patients, independent of troponin or BNP levels [7, 9–15].
It has also been reported that GDF-15 plays a protective
role in heart disease, which may be attributed to the anti-
apoptotic, anti-inflammatory, or anti-hypertrophic effects
demonstrated in animal models [21, 22]. Moreover,
GDF-15 might induce angiogenesis, which plays an essen-
tial role in the recovery of damaged myocardium [23]. A
prolonged increase in GDF-15 levels after episodes of is-
chemia and reperfusion may be associated with increased
levels of oxidative stress, inflammation, and infarct heal-
ing, and the increase of GDF-15 requires for enhanced
oxidative metabolism and tissue repair [9]. Accordingly,
one feasible explanation for the predictive role of GDF-15
is that higher levels of GDF-15 indicate a greater extent of
myocardium damage and the risk of adverse remodeling.
GDF-15 is also strongly induced in other cardiovascular
conditions, such as heart failure [21], Takotsubo cardio-
myopathy [24], and atherosclerosis [25].
In this meta-analysis, clear inclusion and exclusion
criteria were required for study inclusion. The qualityFig. 3 The forest plots of combined hazard rate of GDF-15 with mortality oof the current study was well assessed using the
MOOSE system. There was no publication bias, ac-
cording to the funnel plots (Fig. 3). Heterogeneity
was high among the “<1200 ng/L vs. 1200–1800 ng/
L” subgroup of recurrent MI patients. The following
sensitive test showed that this heterogeneity disap-
peared (I2 = 0 %) when we removed an included study
from the Netherlands [11], thus indicating that the
heterogeneity might have resulted from ethnicity dif-
ferences, as the remaining two studies included
samples from Sweden. The other comparisons showed
low or no heterogeneity (I2 < = 27 %), suggesting that
our study results were reliable.
There are ethnic differences in GDF-15 levels. In
Europeans, the median GDF-15 concentration ranged
from 1244 to 1635 ng/L, whereas it was much lower in
Asians (650 ng/L) [26]. However, the Asian study cohort
was limited in number, and future well-designed studies
with different ethnicities are warranted.
Limitations
Although individual patient data from eight eligible
studies were included in our meta-analysis, this study
had some limitations. First, the definitions of all-cause
mortality and cardiovascular mortality were not con-
firmed. Among the studies included, only two studies
provided detailed information [7, 9]. For the recurrent
MI patients without causes of death, we only performed
subgroup analyses for “recurrent MI”. Second, although
the revealed heterogeneity was low for most of the com-
parisons, GDF-15 levels might be influenced by many
factors, including age, male gender, current smoking,
symptomatic heart failure, reduced kidney function, and
diabetes mellitus, among others [27]. Third, the ACS
patients were treated with different treatment strategies,
which might alter the GDF-15 levels. Fourth, ther recurrent of MI
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times, therefore the GDF-15 levels may change by differ-
ent time after ACS events, however, evidence found that
GDF-15 levels showed small alterations several months
after ACS events [28], hence, we could not give a
judgment if the different time of the tests of the GDF-15
would influence our findings. Fifth, the follow-up dura-
tions differed in each study. In addition, one study [13]
recorded the initial mortality rate 6 months after the
ACS occurred, which might slightly alter our study
results. Sixthly, the HR of different studies were obtained
at different time after the ACS happened, which may
slightly influence the results, however, the combined
data showed no heterogeneity (I2 = 0 %).
Conclusion
The present study suggests that GDF-15 is a strong
predictor of mortality and recurrent MI in ACS prognosis.
Thus, it has the potential to become a clinically useful
novel biomarker that can provide independent prognostic
information and also help to direct optimal treatment
strategies. Current ongoing clinical trials are needed to
further clarify the benefits of GDF-15 in predicting the
prognoses of patients with acute coronary syndrome.
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